Evidence map›Paper›PMID 40051661›Full record

ArticleNeuro-oncology advances

A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma.

Benjamin M Ellingson, Qunicy Okobi, Robert Chong, Rhea Plawat, Eva Zhao, Andrei Gafita, Ida Sonni, Saewon Chun, Emese Filka, Jingwen Yao and 8 more

Erratum issued Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03732352 (Creating Metabolic Vulnerabilities in Patients with EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR with Osimertinib), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03732352 phase2completednot on this map

Creating Metabolic Vulnerabilities in Patients with EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR with Osimertinib

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2018 to 2024Enrolled12ConditionsEGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent GlioblastomaArmsFludeoxyglucose F-18, Osimertinib, Positron Emission Tomography
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Benjamin M EllingsonJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-2764-6640
Qunicy OkobiDepartment of Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Robert ChongDepartment of Neurology, University of California, Los Angeles, Los Angeles, California, USA.
Rhea PlawatDepartment of Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Eva ZhaoDepartment of Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, California, USA.
Andrei GafitaJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.
Ida SonniJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.
Saewon ChunDepartment of Neurology, University of California, Los Angeles, Los Angeles, California, USA.
Emese FilkaDepartment of Neurology, University of California, Los Angeles, Los Angeles, California, USA.
Jingwen YaoUCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Donatello TelescaDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA.
Shanpeng LiDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA.
Gang LiDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA.
Albert LaiDepartment of Neurology, University of California, Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-7265-2986
Phioanh NghiemphuDepartment of Neurology, University of California, Los Angeles, Los Angeles, California, USA.
Johannes CzerninJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.
David A NathansonJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.
Timothy F CloughesyJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-8656-7483

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Quantitative molecular MR-PET imaging of glycolysis in glioblastomaR01CA279984 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Benjamin M. Ellingson, David A. Nathanson · 2023 to 2026
$2.4M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA279984
6 · The paper itself

Abstract

Background: To demonstrate the potential value of Methods: A GBM PDOX mouse model study was performed concurrently with an open-label, single-arm, single-center, phase II study of osimertinib (NCT03732352) that enrolled 12 patients with rGBM with EGFR alterations. Patients received osimertinib daily and 3 Results: GBM PDOX models suggest osimertinib has limited impact on both Conclusions: This study demonstrated the feasibility of using FDG PET as a clinically reliable imaging biomarker for assessing EGFR inhibition in GBM, while revealing osimertinib's limited impact on both metabolic activity and tumor growth in GBM, findings that were concordant between preclinical and clinical observations.

Indexed as

EGFRFDG PETglioblastomaimaging biomarkermolecular imagingosimertinib

Identifiers

PMID40051661
PMCPMC11883343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.